文献速递病毒性肝炎

美国成人丙型肝炎诊断检测策略的成本效果分析

Cost-Effectiveness Analysis of Testing Approaches for Diagnosis of Hepatitis C Among US Adults.
PubMed 文献 · Clin Infect Dis · 2025-01-01

该研究用决策树与马尔可夫模型评估美国平均风险成人中四种丙肝检测策略的成本效果。与现行抗-HCV后自动NAT策略相比,抗-HCV后自动HCVcAg再NAT策略每人节省0.26美元且诊断数与健康结局相同;平行检测和直接NAT策略每人成本增加8.60和21.48美元,但诊断、治疗感染数和QALY增加。病毒优先策略可能具有成本效果。

要点

  • 抗-HCV阳性后自动HCVcAg再NAT策略与现行策略诊断数相同,每人节省0.26美元。
  • 平行抗-HCV与HCVcAg检测策略每人成本增加8.60美元,诊断和治疗感染数及QALY增加。
  • 直接HCV RNA NAT策略每人成本增加21.48美元,诊断和治疗感染数及QALY增加。

核心结论

  • 与现行HCV检测策略相比,病毒优先的HCV检测策略可能是具有成本效果的策略,可增加诊断和健康结局。

研究设计与样本

  • 采用决策树框架和丙肝疾病进展马尔可夫模型,模拟代表美国平均风险成人的队列。
  • 比较四种策略:抗-HCV阳性后自动NAT(对照)、抗-HCV阳性后自动HCVcAg再NAT(干预1)、平行抗-HCV与HCVcAg检测(干预2)、直接HCV RNA NAT(干预3)。
  • 比较成本(2023美元)、质量调整生命年(QALY)和流行病学结局,时间跨度为队列终生。

主要发现

  • 与对照相比,干预1的HCV诊断数和后续健康结局相同,每人节省0.26美元。
  • 干预2每人成本增加8.60美元,诊断感染、治疗感染和QALY增加。
  • 干预3每人成本增加21.48美元,诊断感染、治疗感染和QALY增加。

临床怎么用

  • 病毒优先的HCV检测策略与现行策略相比可能具有成本效果,可增加诊断和健康结局。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnosis of infection with hepatitis C virus (HCV) is the first step to accessing curative treatment, yet many infected adults in the United States are unaware of their infection. Viral-first HCV testing strategies may improve diagnosis. We assessed the cost-effectiveness of several hepatitis C testing strategies compared with the currently recommended testing algorithm. METHODS: We used a decision tree framework with a Markov model of hepatitis C disease progression, to model a cohort representative of US adults at average risk. We modeled 4 strategies: anti-HCV test with automatic nucleic acid test (NAT) for HCV RNA when the anti-HCV result is reactive (comparator); anti-HCV test with automatic hepatitis C core antigen (HCVcAg) test when the anti-HCV result is reactive, followed by NAT for HCV RNA when the HCVcAg result is not reactive (intervention 1); concurrent anti-HCV and HCVcAg tests with automatic NAT for HCV RNA for discordant anti-HCV and HCVcAg results (intervention 2); and NAT for HCV RNA (intervention 3). We compared costs (in 2023 US dollars), quality-adjusted life-years (QALYs) and epidemiologic outcomes for the lifetime of the cohort. RESULTS: Relative to the comparator, intervention 1 resulted in the same number of HCV diagnoses and subsequent health outcomes, with cost savings of $0.26 per person. Interventions 2 and 3 had increased costs per person ($8.60 2 and $21.48, respectively) and resulted in an increase in diagnosed infections, treated infections, and QALYs. CONCLUSIONS: Compared with the current HCV testing approach, viral-first HCV testing approaches are potentially cost-effective strategies that resulted in gains in diagnoses and health outcomes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hall EW, Sandul AL, Kamili S, et al. Cost-Effectiveness Analysis of Testing Approaches for Diagnosis of Hepatitis C Among US Adults. Clin Infect Dis. 2025. PMID: 40396750. doi:10.1093/cid/ciaf166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。